Document Details

Generated Narrative: Bundle TEST PURPOSES ONLY - elocta

Document Subject

Generated Narrative: MedicinalProductDefinition mpdac9f5296bbae6c42cca031529e9fd3c

identifier: http://ema.europa.eu/identifier/EU/1/15/1046/001

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: ELOCTA 250 IU powder and solvent for solution for injection

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-	Country	Jurisdiction	Language
*	EU	EU	en

Document Content

Generated Narrative: Composition composition-en-dac9f5296bbae6c42cca031529e9fd3c

identifier: http://ema.europa.eu/identifier/EU/1/15/1046/001

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - elocta

Attesters

What is in this leaflet

1. What ELOCTA is and what it is used for
2. What you need to know before you use ELOCTA
3. How to use ELOCTA
4. Possible side effects
5. How to store ELOCTA
6. Contents of the pack and other information

ELOCTA contains the active substance efmoroctocog alfa, a recombinant coagulation factor VIII, Fc fusion protein. Factor VIII is a protein produced naturally in the body and is necessary for the blood to form clots and stop bleeding.

ELOCTA is a medicine used for the treatment and prevention of bleeding in all age groups of patients with haemophilia A (inherited bleeding disorder caused by factor VIII deficiency).

ELOCTA is prepared by recombinant technology without addition of any human- or animal-derived components in the manufacturing process.

How ELOCTA works In patients with haemophilia A, factor VIII is missing or not working properly. ELOCTA is used to replace the missing or deficient factor VIII. ELOCTA increases factor VIII level in the blood and temporarily corrects the bleeding tendency.

Do not use ELOCTA:

• if you are allergic to efmoroctocog alfa or any other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor, pharmacist or nurse before using ELOCTA.

• There is a small chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to ELOCTA. Signs of allergic reactions may include generalised itching, hives, tightness of the chest, difficulty breathing and low blood pressure. If any of these symptoms occur, stop the injection immediately and contact your doctor.

• The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all factor VIII medicines. These inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. If your or your child s bleeding is not being controlled with ELOCTA, tell your doctor immediately.

Cardiovascular events If you have heart disease or are at risk for heart disease, take special care when using factor VIII medicines and talk to your doctor.

Catheter-related complications If you require a central venous access device (CVAD), risk of CVAD-related complications including local infections, presence of bacteria in the blood and catheter site thrombosis should be considered.

Documentation It is strongly recommended that every time ELOCTA is given, the name and batch number of the product are recorded.

Other medicines and ELOCTA Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
No effects on ability to drive or use of machines have been observed.

ELOCTA contains sodium This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially sodium-free . However, depending on your body weight and dose, you could receive more than one vial. This should be taken into consideration if you are on a controlled sodium diet.

Treatment with ELOCTA will be started by a doctor who is experienced in the care of patients with haemophilia. Always use this medicine exactly as your doctor has told you (see Instructions for preparation and administration). Check with your doctor, pharmacist or nurse if you are not sure.

ELOCTA is given as an injection into a vein. Your doctor will calculate the dose of ELOCTA (in International Units or IU ) depending on your individual needs for factor VIII replacement therapy and on whether it is used for prevention or treatment of bleeding. Talk to your doctor if you think that your bleeding is not being controlled with the dose you receive.

How often you need an injection will depend on how well ELOCTA is working for you. Your doctor will perform appropriate laboratory tests to make sure that you have adequate factor VIII levels in your blood.

Treatment of bleeding
The dose of ELOCTA is calculated depending on your body weight and the factor VIII levels to be achieved. The target factor VIII levels will depend on the severity and location of the bleeding.

Prevention of bleeding The usual dose of ELOCTA is 50 IU per kg of body weight, given every 3 to 5 days. The dose may be adjusted by your doctor in the range of 25 to 65 IU per kg of body weight. In some cases, especially in younger patients, shorter dosing intervals or higher doses may be necessary.

Use in children and adolescents ELOCTA can be used in children and adolescents of all ages. In children below the age of 12, higher doses or more frequent injections may be needed.

If you use more ELOCTA than you should Tell your doctor as soon as possible. You should always use ELOCTA exactly as your doctor has told you, check with your doctor, pharmacist or nurse if you are not sure.

If you forget to use ELOCTA Do not take a double dose to make up for a forgotten dose. Take your dose as soon as you remember and then resume your normal dosing schedule. If you are not sure what to do, ask your doctor or pharmacist.

If you stop using ELOCTA Do not stop using ELOCTA without consulting your doctor. If you stop using ELOCTA you may no longer be protected against bleeding or a current bleed may not stop.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If severe, sudden allergic reactions (anaphylactic reaction) occur, the injection must be stopped immediately. You must contact your doctor immediately if you experience any of the following symptoms of allergic reactions: swelling of the face, rash, generalised itching, hives, tightness of the chest, difficulty breathing, burning and stinging at the injection site, chills, flushing, headache, low blood pressure, general feeling of being unwell, nausea, restlessness and fast heartbeat, feeling dizzy or loss of consciousness.

For children previously untreated with factor VIII medicines, inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10 patients); however, patients who have received previous treatment with factor VIII (more than 150 days of treatment) the risk is uncommon (less than 1 in 100 patients). If this happens the medicines may stop working properly and you may experience persistent bleeding. If this happens, you should contact your doctor immediately.

The following side effects may occur with this medicine.

Uncommon side effects (may affect up to 1 in 100 people) Headache, dizziness, taste alteration, slow heartbeat, high blood pressure, hot flushes, vascular pain after injection, cough, lower abdominal pain, rash, papular rash, device-related thrombosis, joint swelling, muscle pain, back pain, joint pain, general discomfort, chest pain, feeling cold, feeling hot and low blood pressure.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the vial label after EXP . The expiry date refers to the last day of that month. Do not use this medicine if it has been stored at room temperature for longer than 6 months.

Store in a refrigerator (2 C - 8 C). Do not freeze. Store in the original package in order to protect from light.

Alternatively, ELOCTA may be stored at room temperature (up to 30 C) for a single period not exceeding 6 months. Record on the carton the date that ELOCTA is removed from the refrigerator and set at room temperature. After storage at room temperature, the product must not be put back in the refrigerator.

Once you have prepared ELOCTA it should be used right away. If you cannot use the prepared ELOCTA solution immediately, it should be used within 6 hours. Do not refrigerate the prepared solution. Protect the prepared solution from direct sunlight.

The prepared solution will be clear to slightly opalescent and colourless. Do not use this medicine if you notice that it is cloudy or contains visible particles.

Discard any unused solution appropriately. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

What ELOCTA contains

• The active substance is efmoroctocog alfa (recombinant coagulation factor VIII, Fc fusion protein). Each vial of ELOCTA contains nominally 250, 500, 750, 1000, 1500, 2000, 3000 or 4000 IU efmoroctocog alfa.
• The other ingredients are sucrose, sodium chloride, histidine, calcium chloride dihydrate, polysorbate 20, sodium hydroxide, hydrochloric acid and water for injections. If you are on a controlled sodium diet, see section 2. What ELOCTA looks like and contents of the pack

ELOCTA is provided as a powder and solvent for solution for injection. The powder is a white to off-white powder or cake. The solvent provided for preparation of the solution to inject, is a clear, colourless solution. After preparation, the solution to inject is clear to slightly opalescent and colourless.

Each pack of ELOCTA contains 1 powder vial, 3 mL solvent in pre-filled syringe, 1 plunger rod, 1 vial adapter, 1 infusion set, 2 alcohol swabs, 2 plasters and 1 gauze pad.

Marketing Authorisation Holder and Manufacturer Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm Sweden

This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site: